It is well established that the immune system has the capacity to attack malignant cells. During malignant transformation cells acquire numerous molecular and biochemical changes that render them potentially vulnerable to immune cells. Yet it is self-evident that a growing tumour has managed to evade these host defence mechanisms. The exact ways in which the immune system interacts with tumour cells and how cancers are able to escape immunological eradication have only recently started to be fully elucidated. Understanding the relationship between the tumour and the anti-tumour immune response and how this can be altered with conventional treatments and immune-targeted therapies is crucial to developing new treatments for patients with cancer. In this review, focusing on the anti-tumour T-cell response, we summarize our understanding of how tumours, cancer treatments and the immune system interact, how tumours evade the immune response and how this process could be manipulated for the benefit of patients with cancer.
Introduction
Although anti-cancer immunity involves both the innate and adaptive immune systems, it is generally held that CD8 þ cytotoxic T lymphocytes (CTL) are the most potent anti-tumour effector cell. The T-cell immune response can be broken down into the following steps, all of which need to be fulfilled for effective anti-tumour CTL to be generated (Lake and Robinson, 2005) : (1) tumour antigen(s) must be present, and (2) these must be presented in a context which is seen as dangerous by the immune system; (3) antigens must be acquired and presented by antigen presenting cells (APC) in the draining lymph node; (4) specific T cells must then recognize and respond to tumour antigen by proliferating, exiting the lymph node, recirculating and entering the tumour as CTL and (5) once within the tumour they need to overcome the local immunosuppressive environment before they can kill tumour cells. In addition, memory cells may need to be generated to produce a sustained response.
It is clear that a growing tumour has managed to escape this process. Failure of the anti-tumour immune response can occur at one or more of these steps. Targeting ratelimiting steps with therapies designed to boost the immune response can improve anti-tumour immunity (Yuan et al., 2008) . In addition to specifically targeted immune therapies, it is also now clear that many traditional cancer therapies can improve key aspects of anti-cancer immunity by inducing tumour cell death in a way that is immunostimulatory or by modulating tumourinduced immunosuppression .
Tumour antigens: what the host might 'see' as being different to self Tumours typically express two types of antigen: neoantigens and self-antigens. Neo-antigens (tumour-specific antigens) are derived from mutated self-proteins or oncogenic viruses, and are not expressed in normal tissue. Malignant cells express numerous neo-antigens as a result of genomic instability (Tomlinson et al., 2002; Weir et al., 2007; Srivastava and Srivastava, 2009 ). Most of these mutations do not have functional significance for the tumour cell, but may still provide potential antigenic targets for immune cells. However, oncogenic mutations in genes that drive tumour cell replication make more attractive targets for immunotherapy, as immune escape through loss of gene expression should be incompatible with continued tumour growth.
In addition, tumours can also express normal selfproteins, but in abnormal quantities or locations (tumour-associated antigens) (Schietinger et al., 2008) . Tumour-associated antigens include cancer-testis antigens, for example, MAGE and ESO; differentiation antigens, such as tyrosinase, which are also expressed in the tissue of origin; oncofetal antigens such as aFP and CEA or overexpressed proteins such as Her2 or wild-type p53 (Antonia et al., 2006; Cloosen et al., 2007; van der Bruggen, 2009; Bioley et al., 2009a) .
During T-cell development, T-cell precursors with a strongly self-reactive T-cell receptor are deleted in the thymus, resulting in a T-cell repertoire with a high affinity for foreign antigens and a weak affinity for selfantigens. In addition, self-reactive T cells can be tolerized peripherally following an encounter with an antigen in the absence of an activating stimulus and through the actions of regulatory cells. As tumour neoantigens are 'foreign', in so much as they are not expressed in the thymus, T-cell precursors with high affinity for these antigens escape thymic deletion. In a similar manner, tumour antigens of the cancer-testis group are largely hidden from developing immune cells. In contrast, most other tumour-associated antigens are expressed in other tissues, including the thymus (Cloosen et al., 2007) , resulting in a lymphocyte population that is either deleted or has low affinity for these antigens.
Multiple tumour antigens generate a hierarchy of T-cell responses with dominant antigens producing stronger responses than sub-dominant or cryptic antigens (Wortzel et al., 1983; Nelson et al., 2000; Bundell et al., 2006) . Tumour-specific neo-antigens are dominant over antigens shared with normal tissues (Lennerz et al., 2005) . CTL responses can be generated to weaker antigens, but require higher antigen concentrations and prolonged duration of exposure (Nelson et al., 2000) . Furthermore, patients with differing human leucocyte antigen haplotypes may generate variable immune responses to the same tumour antigens or tumour vaccines because of differing affinity of the antigen for human leucocyte antigen molecules (Bioley et al., 2009b, c) .
Although there is a stronger T-cell repertoire for tumour neo-antigens, the expression of mutated gene products is usually specific to individual tumours, limiting the general applicability of immunotherapy directed at these antigens. Exceptions include genes such as ras, which mutate in a small number of predictable sites and may, therefore, generate epitopes that are shared between patients (Linard et al., 2002) . Recently, Pleasance et al. sequenced the genome of small-cell lung cancer (Pleasance et al., 2009b) and melanoma (Pleasance et al., 2009a) and identified signature mutational patterns of tobacco smoke and ultraviolet radiation, respectively. In three lung cancer cell lines studied, mutations in CHD7, a chromatin remodeller and potential oncogene, were found, suggesting that this technique could potentially identify other neo-antigens shared between patients.
In contrast, tumour-associated self-antigens are more likely to be shared between patients and cancer vaccine strategies to date have mainly focused on tumourassociated antigens because of their broader applicability. However, the T-cell repertoire for tumour-associated antigens is often weak (Cloosen et al., 2007) and tumour-associated antigen targeted immunotherapy can cross-react with normal tissues, inducing autoimmunity (Gilboa, 2001; Dudley et al., 2002 ).
An intact tumour as 'its own vaccine' Generating a strong, tumour-specific response with treatments that are applicable to large patient groups is a challenge for vaccine-based immunotherapy and, to date, it has not been feasible to identify neo-antigens at an individual level. To overcome this, immunotherapies have used autologous tumour vaccines, or autologous mRNA gene transfer, to circumvent the need to identify antigens. Individual gene expression profiling and human leucocyte antigen typing is an alternative approach, but is time consuming, costly and difficult to apply in routine clinical practice. Although the above strategies require adequate, accessible tumour tissue, using the in situ tumour as an antigenic source is an approach that does not require tissue manipulation. Inducing tumour cell death through cytotoxic chemotherapy, radiotherapy or locally administered therapies may alter the amount or the way in which tumour antigens engage with the immune system, through exposure of hidden antigens, increased exposure of antigens present at low concentration or modification of low-affinity antigens. In this way, we can use tumour antigens to prime a more effective immune response without ever knowing their identities; in effect the tumour functions as its own vaccine (van der Most et al., 2006; Jackaman et al., 2008) . Studies using chemotherapy to load tumour antigens have confirmed the feasibility of this notion (Nowak et al., 2003a) .
Danger: how tumour cell death can induce an immune response
The immune system has evolved to ask two main questions of any invading organism-is it different (that is, not self) and is it dangerous? (that is, not innocuous). Almost all vaccines harness those two features (antigen ¼ 'different' plus adjuvant ¼ 'dangerous'); a key aim of tumour immunotherapy is to kill tumour cells in ways that make the death look dangerous to the host.
Presentation of tumour antigens on major histocompatibility complex (MHC) class I molecules by APCs, such as dendritic cells (DCs), is necessary to prime CD8 þ CTL. Alone, however, this is insufficient to generate functional effector T cells, and may in fact induce tolerance. Antigens must also be encountered in the context of danger signals, such as those from microorganisms (pathogen-associated molecular patterns) or from dying or damaged cells (damageassociated molecular patterns) (Matzinger, 2002; Lake and Robinson, 2005) . The mode of cell death is important in determining whether the event is immunogenic or tolerizing. For instance, tumour cells treated with alkylating agents induce upregulation of MHC and co-stimulatory molecules on DCs, and increase (interleukin) IL-12 secretion when compared with tumour cells killed by freeze-thawing or nucleoside analogues, implicating DNA damage as one potential 'danger signal' (Rad et al., 2003) .
Most chemotherapeutic agents kill tumour cells by inducing apoptosis. Apoptosis is a tightly regulated cellular mechanism that follows the activation of caspases by cell-surface death receptors or the release of pro-apoptotic molecules from mitochondria. Orderly breakdown of cellular and chromosomal structures occurs without disruption of the cell membrane and cellular material is packaged into apoptotic bodies (Edinger and Thompson, 2004; Okada and Mak, 2004) . Apoptotic cell death during normal cell turnover does not induce immune responses, as potential antigens are removed by phagocytosis and are not presented in an immunogenic context. However, it is now clear that tumour cell apoptosis is not necessarily an immunologically bland or tolerizing event, and under certain circumstances can be immunostimulatory (Restifo, 2000; Feng et al., 2002) . This is dependent on soluble products released from the dying cell and on cell-surface signalling molecules. Phosphatidylserine is one such molecule. Normally restricted to the inner leaflet of the plasma membrane, during apoptosis it crosses to the outer leaflet and provides an 'eat me' signal to phagocytic cells. Phosphatidylserine promotes the uptake of dying cells by macrophages and induces expression of inhibitory cytokines and suppression of IL-12 production (Kim et al., 2004) . It has an inhibitory effect on DCs, leading to maturation failure and reduced ability to stimulate CTL and interferon (IFN)-g-producing helper T cells (Chen et al., 2004) , effectively downregulating the immune response. Calreticulin is an endoplasmic reticular protein that translocates with ERp57 to the tumour cell surface within hours of exposure to anthracyclines, also functioning as an 'eat me' signal to DC well before phosphatidylserine expression and other apoptotic changes are manifested. In contrast to phosphatidylserine-mediated DC uptake, cells displaying exo-calreticulin following anthracycline exposure are immunogenic, as evidenced by their ability to function as tumour vaccines and to stimulate IFN-g production (Chaput et al., 2007; Obeid et al., 2007; Panaretakis et al., 2008; Tesniere et al., 2010) .
Other substances associated with cell damage may be released during apoptosis, and can provide the danger signals required for immunogenic cell death (Skoberne et al., 2004) . As infection provides a key evolutionary pressure for development of immunity, it is not unexpected that innate pathways closely associated with immune response to infection are involved in this activation. During infection, pattern recognition receptors such as toll-like receptors (TLRs) recognize pathogen-associated molecular patterns and trigger the production of pro-inflammatory cytokines. Endogenous substances derived from dying tumour cells can also function on many of these receptors. These include DNA and RNA and their breakdown products (Xiao, 2009) , heat shock proteins (Feng et al., 2002; Javid et al., 2007) and the nuclear protein high mobility group box-1 (HMGB1) (Tesniere et al., 2010) . Immune activation by HMGB1 from tumour cells is dependent on TLR4. The clinical relevance of this pathway has been shown in anthracycline-treated breast cancer patients, in which the presence of a variant, non-functional TLR4 allele significantly hastened the time to development of metastatic disease (Apetoh et al., 2007b) .
Uric acid is another inflammatory stimulator associated with cell damage, being produced from purine catabolism during DNA and RNA breakdown. It is released from dying cells, stimulating DC maturation and enhancing cytotoxic CD8 responses to antigen in vivo (Shi et al., 2003) . Similarly, ATP is an intracellular molecule that within the extracellular environment is pro-inflammatory. Cell death caused by a number of chemotherapeutic agents is associated with reduced intracellular and increased extracellular ATP levels (Martins et al., 2009) . The NOD-like receptor family pyrin domain containing-3 protein-dependent caspase 1 complex-the 'inflammasome'-appears to mediate the DC immune response to dying tumour cells (Ghiringhelli et al., 2009; Li et al., 2009) . ATP has a high affinity for the purinergic receptor P2X7 on DCs, which in turn activates the inflammasome, resulting in caspase-1-mediated cleavage of pro-IL1B to IL1B. IL1B secretion by DCs is important for the priming of naive CD8 T cells into IFN-g producing cells. Ghiringhelli et al. (2009) . showed that deficiency or blockade of any component of this pathway-ATP, P2RX7, caspase-1, IL1, IFN-g or CD8 T cells-impaired the immune response to oxaliplatin-treated tumour cells.
A number of chemotherapy drugs have now been shown to induce tumour cell death in a way which looks dangerous to the immune system (Chaput et al., 2007; Obeid et al., 2007; Apetoh et al., 2007b; Ghiringhelli et al., 2009; Martins et al., 2009; Tesniere et al., 2010) . In addition, augmenting the anti-tumour immune response through the local administration of agents providing danger signals has an established role in cancer treatment, with historical use of Coley's toxin and with intravesical BCG for bladder cancer. We have observed tumour regression in mice following local injection of TLR agonists (Currie et al., 2008) . Combining these local stimuli with systemic agonist anti-CD40 antibody can generate systemic immune responses and regression of distal tumours in mice (Broomfield et al., 2009) .
Antigen presenting cells: the gateway to immunity or tolerance to tumour antigens
Although T-cell receptors bind with variable specificity and avidity to self-and non-self antigens, T cells themselves do not have the capacity to discriminate dangerous from harmless antigen (Figure 1 ). APCs, especially DCs, fulfil this crucial role by acquiring antigens within tissues, responding to associated danger signals and subsequently displaying antigen to T cells (signal 1) with the appropriate information about the level of danger present (signal 2). In addition, helper (CD4 þ ) T cells recognizing antigen presented on MHC class II licence DCs, through co-stimulation, to promote T-cell activation. Thus, the helper T cell gives a 'second opinion' to the DC so that antigens that have previously been seen as dangerous and have hence generated memory responses are promoted as immunogenic.
All nucleated cells express MHC class I molecules and can display endogenously derived antigen bound to MHC class I molecules to CD8 T cells, but only 'professional' APCs can provide the additional co-stimulation needed to activate naive T cells. Endogenous antigen is generated from self-or viral proteins through the actions of proteosomes within the cytosol. It is then transported to the endoplasmic reticulum in a process dependent on the transporter associated with antigen processing (TAP), loaded onto MHC class 1 and trafficked into the plasma membrane. In contrast, exogenous antigens, such as those from tumours, are taken up by APCs into endosomes and loaded on MHC class II molecules within the endocytic compartment. CD4 T cells are then able to bind antigen shown on MHC class II molecules on the cell surface (Guermonprez et al., 2002) .
However, some DCs are also able to present exogenous antigens on MHC class I molecules for recognition by CD8 T cells, termed as 'cross-presentation' (Albert et al., 1998) . Cross-presentation of tumour antigen bound to MHC class I is a constitutive feature during many types of tumour growth Robinson et al., 1999 Robinson et al., , 2001 ) even in the absence of any anti-tumour CTL activity. Cell-bound antigen is presented more efficiently than soluble antigen (Li et al., 2001 ) and the degree of cross-presentation is dependent on the amount of antigen present (Nelson et al., 2000) . Cross-presentation is dependent on TAP, and hence it was initially thought that for cross-presentation to occur, following cytosolic degradation by proteosomes, exogenous protein had to join the endogenous pathway in the endoplasmic reticulum (Brossart and Bevan, 1997) . However, recent study suggests that TAP is present in endosomes and transports antigen destined for cross-presentation back into the endosome from the cytoplasm for loading onto MHC I . Interestingly, TAP levels in endosomes are regulated by the TLR4-MyD88 pathway, implying that TLR danger signals can upregulate signal 1 on the DC as well as signal 2 . In some DCs the routing of soluble, endocytosed antigen into the cross-presentation pathway is determined at the point of cell entry by the endocytosis receptor involved (Burgdorf et al., 2007) . In contrast, cell associated or particulate antigens are internalized within phagosomes. These antigens can be transported to the cytosol for class I processing and TAP-dependent cross-presentation or can be degraded into class II peptides by pHdependent lysomal proteases and loaded onto MHC class II within the phagosome (Houde et al., 2003; . Regulation of the pH within the proteosome seems to determine to which route antigen is directed (Savina et al., 2006) . In addition, although most have found cross-presentation to be TAP dependent, it has been observed that some exogenous antigens may be loaded directly onto MHC I within the endosome in a TAP-independent pathway (Castellino et al., 2000) .
The fate of the T cell whose T-cell receptor binds to cross-presented antigen, and whether it becomes primed or inactivated as result of this encounter, is critically dependent on the state of maturation of the DC; activated DCs cross-prime, whereas non-activated DCs cross tolerize. Immature DCs are inefficient at cross-presenting antigen and do not express the co-stimulatory molecules required to activate T cells. DC maturation is initiated by 'danger signals' from pathogens or damaged or dying cells and by inflammatory cytokines, including IFN-g (Brossart and Bevan, 1997) . In addition, ligation of CD40 on DCs is a potent inducer of IL12 secretion and increases their capacity to activate T cells (Cella et al., 1996) . CD40L is usually provided by helper T cells, consistent with the finding that CD40 activation circumvents the need for CD4 T cell help (Bennett et al. maturation results in increased antigen uptake, upregulation of MHC expression (Cella et al., 1997) , and expression of co-stimulators CD80 (B7-1) and CD86 (B7-2) (Rad et al., 2003) . During maturation, DCs migrate from tissues to draining lymph nodes, downregulating endocytic capacity and MHC class II synthesis en route, meaning that antigen presented to T cells is restricted to that which was internalized at the time any danger signal was encountered (Guermonprez et al., 2002) .
Promoting the CD8 T cell response: overcoming the reluctance of T cells to become activated and attack tissues Priming of CD8 T cells by mature DC in the draining lymph node requires several signals: T-cell receptor binding to antigen coupled to MHC class 1, ligation of CD28 on the T cell by CD80 or CD86 on the DC and inflammatory cytokines such as IL-12 and type 1 INFs. However, an effective anti-tumour response also requires that these cells proliferate, survive in the circulation, enter the tumour and fulfil their effector function (Lake and Robinson, 2005) .
There is evidence that CD4 þ cells have a critical role in this process. The addition of tumour antigen-specific CD4 þ cells to a CD8 þ adoptive transfer treatment strategy in mice led to sustained accumulation of tumour-specific CD8 þ cells in tumour and lymphoid tissues when compared with CD8 þ transfer alone. Cytotoxic activity of the CTLs was maintained and mice were protected from tumour growth (Marzo et al., 2000) . Persistent CD4 þ help and IL-2 secretion are required to maintain CD8 cell function and numbers (Antony et al., 2005) . Direct cell-cell contact from CD4 cells can also protect effector CD8 cells from activationinduced cell death (Kennedy and Celis, 2006) . Subsets within the CD4 þ helper T-cell population are defined by cytokine expression profiles, and the tone of this response is an important determinant of tumour rejection (Hamilton and Bretscher, 2008) . Until recently this was thought to be polarized between Th1 cells secreting inflammatory cytokines IFN-g, tumour necrosis factor-a and IL-2, and the IL4-, IL5-and IL10-predominant Th2 response. However, recently identified CD4 subset Th17 also appears to have a role within the tumour microenvironment, with adoptive transfer of Th17 cells in a mouse melanoma model promoting tumour DC infiltration, increased antigen presentation and a strong anti-tumour CD8 response (MartinOrozco et al., 2009) . In a clinical context, high levels of Th17 cells within ovarian tumours were associated with effector T-cell cytokines tumour necrosis factor-a, IL2 and IFN-g and Th1 type chemokines, with high ascitic levels of the Th17 signature cytokine, IL-17, being associated with prolonged survival (Kryczek et al., 2009) .
Help from CD4 cells during CD8 priming gives rise to CD8 cells that are not only able to function as effector CTL, but on re-stimulation with antigen undergo further clonal expansion leading to the generation of memory cells (Janssen et al., 2005; Bannard et al., 2009; Feau and Schoenberger, 2009) . This is again dependent on IL-2 secretion , consistent with the finding that mice cured of tumour through the adoptive transfer of Th1 cells acquired immunological memory, whereas those cured by transfer of Th2 cells did not (Nishimura et al., 2000) . In contrast, those CD8 cells that do not receive CD4 help during priming die following secondary contact with antigen, partly mediated by upregulation of the TRAIL receptor DR5 (Janssen et al., 2005) .
Although the role of CD4 helper cells in the activation and maintenance of CD8 T cells and the generation of memory is well established, less is known about their precise role following secondary encounter with antigen within the tumour. As CD4 cells enhance tumour CD8 infiltration (Marzo et al., 2000) , it is assumed that through induction of co-stimulation plus cytokine and chemokine production, helper T cells facilitate secondary expansion and survival of CTLs (Kennedy and Celis, 2008) . In a metastatic murine tumour model, the presence of memory CD4 cells enhanced secondary expansion of memory CD8 cells, increased tumour infiltration of activated CD8 cells and controlled tumour growth (Hwang et al., 2007) . However, because it is difficult to track these cells experimentally within tumours, it is unclear whether this secondary help is mediated directly to CTLs or through further interactions with APCs.
Why does an anti-tumour T-cell response still fail to eradicate tumours?
The importance of a robust effector T-cell response in mediating successful outcomes to immunotherapy has been recently shown in a clinical human papillomavirus vaccine trial for pre-malignant vulval intraepithelial neoplasia, in which measured T-cell responses strongly correlated with regression of lesions (Kenter et al., 2009; Welters et al., 2010;  Figure 2 ). However, in other clinical trials of tumour vaccines against larger, invasive malignancies the effective generation of tumour antigenspecific T cells in peripheral blood has not predicted clinical efficacy Gajewski et al., 2006) . This disparity may reflect the weaker activity of T cells generated by vaccines targeting shared self-tumour antigens compared with those directed against viral neoantigens. It may also reflect the presence of a number of other barriers to effective immunotherapy in established invasive tumours compared with premalignant lesions.
Tumour reactive CTLs may be ineffective because they remain in the periphery or in the draining lymph node without actually infiltrating the tumour (Stumbles et al., 2004), or they may disseminate to the tumour but are unable to mediate anti-tumour activity . This suggests that the anti-tumour T-cell response can fail downstream of the induction phase.
Failure of activated T cells to continue to expand and maintain function T-cell anergy can occur as a result of inadequate costimulation during priming, or can be acquired during later phases of clonal expansion after adequate initial activation (Deeths et al., 1999; Mescher et al., 2007) . Cells that become anergic may be able to fulfil effector functions, but are unable to expand further or generate memory cells; this state can be reversed by IL-2, typically supplied by CD4 cells. Acquired anergy provides an inherent brake to the initial rapid CD8 T-cell response, which will recede after a few rounds of cell division unless further CD4 help is supplied. T cells may also become tolerized following persistent peripheral exposure to antigen, for example, in the setting of a growing tumour. This leads to a failure to proliferate and produce IL-2 in response to antigen, although cytotoxic activity may be retained (Tanchot et al., 1998; Ohlen et al., 2002) . These findings are potentially relevant in human cancer, with Beyer et al. (2009) identifying both tumour reactive and non-tumour reactive T-cell clones co-existing in cancer patients; non-reactive cells had not simply been suboptimally activated, but had altered molecular programmes leading to division arrest anergy.
Activated T cells may be switched off by some tumours
Inhibitory co-receptors, including CTLA4 and PD1, appear to have a major role in inducing and maintaining peripheral T-cell tolerance. They are expressed on activated T cells and interact with molecules of the B7 family that are found on APCs, but are also expressed by many tumours (reviewed in Zou and Chen, 2008) . CTLA-4 is upregulated during T-cell activation and causes competitive inhibition of B7-CD28 induced T-cell activation, modulates intracellular signalling pathways and leads to decreased IL-2 production, impaired T-cell receptor signalling and cell-cycle arrest, particularly in the early post-activation phase (Hodi, 2007) . Anti-CTLA-4 treatment has been trialled in melanoma and other cancers with some evidence of clinical efficacy (Wolchok and Saenger, 2008; Yuan et al., 2008) . The expression of PD-L1 (B7-H1), a ligand for PD-1, is upregulated by IFN-g (Blank et al., 2004) and has been observed in many tumour types, often being associated with a poor prognosis (Zou and Chen, 2008) . PD-1/PD-L1 interactions impair anti-tumour T-cell responses in mice, which is reversed in PD-1-deficient mice or by blocking PD1 (Blank et al., 2004) . Mechanistically, expression of PD-L1 by tumours induces T-cell apoptosis (Dong et al., 2002) , induces production of IL-10 and may mediate regulatory T cell (Treg)-suppressive activity (Zou and Chen, 2008) . PD-1/PD-L1 inhibition strategies in patients with cancer are currently in early phase clinical trials. Although both CTLA-4 and PD-1 induced T-cell tolerance in an autoimmune diabetes model, only PD-1 was able to maintain tolerance after induction (Fife et al., 2006) . It is unclear whether this observation will be important in tumour models or clinical testing. 
Suppression by regulatory T cells
Regulatory T cells modulate the immune response and function by downregulating potentially harmful autoreactive T cells, and Treg defects are associated with the development of autoimmune disease (Costantino et al., 2008; Poitrasson-Riviere et al., 2008) . Although other types of suppressive cell have been identified, most regulatory T cells are characterized by expression of surface CD25 and by intracellular FOXP3, a transcription factor that mediates many of their inhibitory capabilities (Fontenot et al., 2005) . It is unclear what proportion of Tregs react with specificity to tumour antigens (Wang et al., 2005) , or whether they are recruited through the recognition of shared self-antigens that are co-expressed by tumour cells (Nishikawa et al., 2003; Darrasse-Jeze et al., 2009) . Tregs can inhibit effector T-cell responses during both the induction (Darrasse-Jeze et al., 2009) and the effector stages (Huehn et al., 2004; Sarween et al., 2004) by a number of mechanisms, such as through direct ligation of CTLA-4 with CD80 or CD86 on effector T cells, by promoting the development of inhibitory DCs, or through the generation of inhibitory cytokines, transforming growth factor-b and IL10 (von Boehmer, 2005) . The importance of this subset has been shown in vivo, with Treg depletion mediating tumour regression in mice (Onizuka et al., 1999; Rudge et al., 2007) .
Increased Treg infiltration has been shown in many human tumour types, usually associated with decreased anti-tumour immune responses and worse prognosis (reviewed in Beyer and Schultze, 2006) . However, Treg accumulation is not a universal feature of human cancer, implying a lack of immune response to the tumour or other means of regulation such as myeloidderived suppressor cells. Furthermore, in colorectal cancer, two independent cohorts showed improved survival in patients with a high frequency of tumourinfiltrating Tregs (Frey et al., 2009; Salama et al., 2009) . One explanation is that this finding reflects increased immunogenic stimuli within these tumours-due to either tumour antigens or gut pathogens-and a subsequent robust immune response.
The prognostic significance of Tregs in many human cancers, together with the success of Treg depletion in murine tumours, suggests Treg depletion may be used as a clinical therapeutic strategy. This may be achieved through anti-CD25 therapies, which have shown effective Treg depletion and enhanced CTL response to subsequent peptide vaccination (Rech and Vonderheide, 2009) . However, a different Treg depletion strategy using the cytotoxic agent cyclophosphamide may be more readily translatable to the clinic. At high doses, cyclophosphamide is cytotoxic and causes immunosuppression, but at low doses it preferentially depletes numbers of Tregs (Ghiringhelli et al., 2004 van der Most et al., 2009b) and impairs Treg function (Lutsiak et al., 2005) . A single dose of cyclophosphamide-depleted Tregs and when followed by an immunotherapy cured mice with established tumours (Ghiringhelli et al., 2004) . In humans, low-dose oral cyclophosphamide in patients with advanced cancer selectively depleted the Treg subset and enhanced the cytotoxic capacity of T and natural killer cells . We are currently conducting a phase 1 trial to determine the optimal dosing strategy for low-dose cyclophosphamide in conjunction with pemetrexed and cisplatin chemotherapy, and the effects on numbers, proliferation and activation of Tregs and other T-cell subsets in patients with malignant mesothelioma and non-small cell lung cancer.
Immune escape within the tumour microenvironment Cytotoxic T cells recognize antigen bound to MHC class 1. However, reduced expression of MHC class 1, usually because of epigenetic regulation of TAP expression, has been observed in many tumour types and associated with a poor prognosis in patients with colorectal cancer (Watson et al., 2006) . 'Darwinian' selection of these resistant clones through intrinsic or therapeutic immune pressure may explain why some patients who initially respond to immunotherapy then subsequently relapse (Restifo et al., 1996) .
Changes in expression patterns of non-antigenic molecules may also alter traffic to the tumour. Villablanca et al. (2010) recently discovered that human and mouse tumours can subvert the migratory ability of mature DCs by the expression of LXRa ligands. LXRs bind to oxidized cholesterol and when activated on DCs inhibited expression of CCR7, a chemokine required for DC migration to the draining lymph node. This resulted in impaired DC migration to draining lymph nodes, reduced T-cell priming and impaired anti-tumour activity.
Immunosuppressive cytokines within the tumour also impair immune responses and transforming growth factor-b has been implicated in many different types of cancer (Elliott and Blobe, 2005) . Transforming growth factor-b induces expansion of Treg (Ghiringhelli et al., 2005) and inhibits T-cell effector function (Ahmadzadeh and Rosenberg, 2005) . Interventions targeting transforming growth factor-b have been shown to reduce tumour growth in vivo, and to enhance the effectiveness of other immunotherapies (Marzo et al., 1997; Kim et al., 2008) . Metabolic dysregulation also contributes to local immunosuppression. The enzyme indolamine 2,3-dioxygenase (IDO) is expressed in numerous cancers (Uyttenhove et al., 2003) . It is upregulated by IFN-g and causes tryptophan breakdown, which leads to T-cell apoptosis (Lob et al., 2009) . Interventions aimed at silencing IDO expression have shown anti-tumour activity in a mouse melanoma model (Zheng et al., 2006) .
Cancer therapies that induce tumour cell death can enhance the immune response
Cytotoxic chemotherapy often causes lymphopenia and neutropenia and until recently the notion that chemotherapy could synergize with immunotherapy was not considered plausible. However, it is now clear that chemotherapy can have immunostimulatory effects at a number of different points in the anti-tumour immune response. In causing lymphopenia, chemotherapy depletes regulatory T cells as well as those T cells that have been tolerized to tumour antigens. Following cyclical chemotherapy-induced lymphopenia, homoeostatic proliferation occurs, restoring T-cell numbers. This phenomenon potentially offers a window to skew the regenerating T-cell response back towards active antitumour activity. Depletion of regulatory T cells by cyclophosphamide (Ghiringhelli et al., 2004 Lutsiak et al., 2005; van der Most et al., 2009b) or depletion of myeloid-derived suppressor cells with gemcitabine (Suzuki et al., 2005) may enhance antitumour activity through removal of negative regulation. Lymphodepletion in combination with tumour vaccines has shown efficacy in mice (Dummer et al., 2002; Hu et al., 2002) and humans (Dudley et al., 2002) .
Additional mechanisms for immune modulation following chemotherapy include increased antigen release, and upregulation of immunogenic surface molecules. Apoptotic tumour cell death increases the quantity of antigen released and augments crosspresentation by mature DCs (Rovere et al., 1999) . Chemotherapy-induced cell death can also be qualitatively immunogenic through upregulation of surface calreticulin (Chaput et al., 2007; Obeid et al., 2007; Panaretakis et al., 2008) or release of intracellularderived 'danger signals' (Apetoh et al., 2007a, b; Ghiringhelli et al., 2009; Martins et al., 2009) . Treatment with gemcitabine results in increased antigen crosspresentation and priming of tumour-specific CD8 cells (Nowak et al., 2003a) . Chemotherapy can also sensitize those cells not directly lysed by treatment to subsequent killing by immune cells, through upregulation of death receptors Fas (CD95) or TRAIL receptors (DR5) (Mattarollo et al., 2006; van der Most et al., 2009a) .
Radiotherapy can also stimulate an immune response, as evidenced by the phenomenon known as the abscopal effect, in which unirradiated distal metastases shrink following local primary radiation (Kaminski et al., 2005) . Radiotherapy increased MHC 1 peptide presentation in murine tumours and these tumours expressed neo-antigens that were recognized by CTLs. This strategy enhanced the effectiveness of a subsequent adoptive transfer immunotherapy (Reits et al., 2006) .
Novel molecularly targeted therapies are increasingly used as systemic therapy in a range of solid tumours, either as single agents or in combination with chemotherapy. Multiple classes of drugs are under development, including single-and multiple-target tyrosine kinase inhibitors, epigenetic modulators, vascular targeting agents and proteosome inhibitors. Many have not been assessed for their effects on immune response other than gross observations of lymphocyte numbers in human clinical trials. Nevertheless, reports including inhibition of Tregs with enhanced immune response (Larmonier et al., 2008) , abrogated antigen-specific memory responses (Sinai et al., 2007) and reduction in myeloid-derived suppressor cell numbers (Ko et al., 2009 ) are emerging. Indeed, study showing differential effects on DC function and subsequent T-cell responses between the tyrosine kinase inhibitors sorafenib and sunitinib (Hipp et al., 2008) , which are both used clinically in renal cell carcinoma, shows that we cannot extrapolate from the effects of one agent to a class effect. The functional relevance of these changes in human disease, in combination with cytotoxic chemotherapy, or in combination with immunotherapy is unclear.
Combining immunotherapy with other treatments to cure cancer Multimodality therapy already achieves a proportion of cures in patients with early stage cancers. A key challenge for cancer therapy is to improve outcomes in patients with advanced disease. Many murine studies have shown responses to immunotherapy in very early tumours that cannot be replicated with a larger tumour burden. These very small tumours are unlikely to be representative of most human cancers. However, murine studies have also shown that combining different types of immunotherapies, or combining immunotherapy with chemotherapy, can lead to responses against larger tumours and distal disease (Jackaman et al., 2003 (Jackaman et al., , 2008 Nowak et al., 2003b; Broomfield et al., 2009) . A number of clinical trials of chemoimmunotherapy have been reported with some promising results, although larger randomized controlled trials are still required (reviewed in Zitvogel et al., 2008) .
Immunotherapy in the context of surgery is also interesting, with intriguing paradoxical results following complete or partial debulking in a mouse model. Although either partial or complete resection of large tumours followed by chemoimmunotherapy led to the same high (480%) cure rate (Broomfield et al., 2005) , only partial removal generated long-term anti-tumour memory. This suggests that debulking surgery can reduce tumour burden and tumour-associated immunosuppression to a level in which chemoimmunotherapy can be curative, but that continued antigen presence is needed for memory to be established. These results could imply that patients currently considered unresectable may benefit from debulking surgery as part of a multimodality treatment strategy, and also that those in whom complete resection is achievable may benefit from a continued antigenic stimulus such as a vaccine during adjuvant treatment.
Why has tumour immunotherapy largely failed so far?
In patients with cancer, tumours are already engaging with the immune system. The goal of immunotherapy is to boost this immune response, or to remove whatever is limiting it, such that the balance shifts from tolerance to rejection. The failure of an immunotherapy could be because of limiting factors at any point in the induction or effector phase. There may be inadequate quantity of tumour antigen, or in the case of vaccine-based treatments, targeting shared, self-antigens may produce only weak T-cell responses, insufficient to cause tumour regression. There may be inadequate danger signals to generate strong responses to these antigens. Location of therapy could be important in that treatments may not be providing adequate stimulation in the draining lymph node where T-cell priming occurs. Primed CTLs may be failing to kill tumour cells because of regulatory cell suppression or local tumour escape mechanisms. It may be that a number of these limiting points need to be targeted simultaneously by more than one therapy before an effective immune response is generated.
The conventional oncology-testing field for new treatments is metastatic disease, which has failed multiple lines of therapy. Such a high tumour burden with its associated levels of immunosuppression may be a too high a hurdle for immunotherapy, which works best with less disease and may be best applied in conjunction with other treatments. Timing of immunotherapy regarding other treatments is likely to be important. The widely held belief that chemotherapy or surgery is antagonistic to immunotherapy has meant that there has often been a delay of a few weeks between these treatments such that the optimum window for synergy with immunotherapy has passed.
Outlook for the future
Tumour cell death can be immunogenic and this can be harnessed to improve outcomes for patients with cancer. It may be possible to overcome the problem of antigen specificity by tailoring immunotherapies to individuals based on tumour gene expression profiles and human leucocyte antigen typing. However, this approach is likely to be both costly and time consuming. A more readily translatable method may be to manipulate the way tumour cells are killed and are sensed by immune cells such that pre-existing antigens within the tumour are able to provoke tumour-specific cytotoxic T-cell responses. One can envisage a situation in which chemotherapeutic agents are selected to kill tumour cells in a way that is immunogenic, or sensitize tumour cells to immune-mediated cell death. Further strategies involving immune stimuli and blockade of tumourinduced immunosuppression could then be applied to promote this immune response. This might involve tumour vaccines, local inflammatory stimuli or regulatory T-cell depletion. In those with high tumour burdens, debulking surgery may be helpful to reduce the tumour load to a level in which these other treatments are more effective.
Immunotherapies have the potential to become effective treatments for patients with cancer. It seems likely that immunotherapy will be most efficacious as part of multimodality treatment that may involve chemotherapy, surgery or radiotherapy. As the role of molecularly targeted therapies evolves, these drugs must also be studied in the context of their interaction with the immune system. It is now clear that these treatments are not necessarily immunosuppressive and under certain circumstances can be used to boost the immune response. Elucidating the precise mechanisms by which tumour cell death and cancer therapies interact with the host response will hopefully give us the understanding to develop more effective treatments for malignant diseases in the future. Immune response to treat cancer HJ Steer et al
